Searching…
Information on acquisition, funding, cap tables, investors, and executives for AkaRx. Use the PitchBook Platform to explore the full profile.
AkaRx, Inc., a biopharmaceutical company, develops therapeutic treatments for unmet medical needs. Its product includes AKR-501, an orally-available small molecule for use in the treatment of thrombocytopenia. The com...
Jun 23, 2025 · Explore AkaRx's in-depth company profile, including funding details, key investors, leadership, and competitors.
Jan 6, 2026 · 如果含量偏低，会造成相应的系列症状。 阿伐曲泊帕片-血小板生成素受体激动剂（TPO-RA），由美国AkaRx公司研发，是一种治疗低血小板症的药物，可以提高人体内的血小板数量，从而达到预防或治疗出血等症状。
Dec 1, 2004 · Company profile page for AkaRx Inc including stock price, company news, executives, board members, and contact information
AkaRx, Inc., a biopharmaceutical company, develops therapeutic treatments for unmet medical needs. Its product includes AKR-501, an orally-available small molecule for use in the treatment of thrombocytopenia. The com...
苏可欣最初由美国生物制药公司 AkaRx 开发，该公司专注于血液疾病和肿瘤领域创新药物的研究。 2014年，复星医药通过收购AkaRx的母公司，获得了该药物在中国及部分亚洲地区的权益。 目前，复星医药负责该药物在中国市场的生产、注册及销售。
